AbbVie Inc. ABBV
Set alert
286.80 USD -2.04 -0.71%
As of Nov 3, 3:05 PM ET
286.50 Day range 291.32
197.38 52-week range 294.89
- YTD
- +25.52%
- 1 year
- +35.31%
- Open
- 288.69
- Prev close
- 288.84
- Mkt cap
- 506.88B
- Vol
- 2.48M
- Avg vol
- 4.74M
- EPS
- 5.82
- P/E
- 49.29
- Div yield
- 2.38%
More statistics
- Low
- 286.50
- High
- 291.32
- Forward P/E
- 17.88
- Beta
- 0.19
- Short ratio
- 3.22
- Inst. own
- 77.39%
- Dividend
- 6.92
- Ex-div date
- Jan 14, 2027
- Earnings
- Feb 3, 2027
- 50-d avg
- 269.29
- 200-d avg
- 237.10
- 1y target
- 298.50
5Y chart
Events in this range
- Jan 13, 2022Dividend: 1.41
- Apr 13, 2022Dividend: 1.41
- Jul 14, 2022Dividend: 1.41
- Oct 13, 2022Dividend: 1.41
- Jan 12, 2023Dividend: 1.48
- Apr 13, 2023Dividend: 1.48
- Jul 13, 2023Dividend: 1.48
- Jul 14, 2023Dividend: 1.48
- Oct 12, 2023Dividend: 1.48
- Jan 12, 2024Dividend: 1.55
- Jan 15, 2024Dividend: 1.55
- Apr 12, 2024Dividend: 1.55
- Jul 15, 2024Dividend: 1.55
- Oct 15, 2024Dividend: 1.55
- Jan 15, 2025Dividend: 1.64
- Apr 15, 2025Dividend: 1.64
- Jul 15, 2025Dividend: 1.64
- Oct 15, 2025Dividend: 1.64
- Oct 31, 2025Earnings: 1.86; estimate 1.77; surprise 5.08%
- Jan 16, 2026Dividend: 1.73
- Feb 4, 2026Earnings: 2.71; estimate 2.65; surprise 2.26%
- Apr 15, 2026Dividend: 1.73
- Apr 29, 2026Earnings: 2.65; estimate 2.59; surprise 2.32%
- Jul 15, 2026Dividend: 1.73
- Jul 31, 2026Earnings: 3.65; estimate 3.61; surprise 1.11%
- Oct 15, 2026Dividend: 1.73
- Oct 30, 2026Earnings: 3.82; estimate 3.73; surprise 2.41%
- Nov 2, 2026Rating: Canaccord Genuity · Buy → Buy
- Nov 2, 2026Rating: RBC Capital · Outperform → Outperform
- Nov 2, 2026Rating: Wells Fargo · Overweight → Overweight
- Nov 2, 2026Rating: Guggenheim · Buy → Buy
- Nov 2, 2026Rating: Morgan Stanley · Overweight → Overweight
- Nov 2, 2026Rating: Leerink Partners · Outperform → Outperform
Signals (97)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| RSI: Overbought | Sep 29, 2025 | 1 year ago |
| RSI: Overbought | Sep 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 21, 2025 | 1 year ago |
Newest 20 of 97.
Analyst view
Consensus: buy
Buy
Price target (mean) 298.50 +4.1% upside
Now 286.80
- Target (low)
- 200.00
- Target (mean)
- 298.50
- Target (high)
- 350.00
Ratings (0m) 29 23 buy · 5 hold · 1 sell
- Strong buy7
- Buy16
- Hold5
- Sell0
- Strong sell1
Recommendation trend
- This month 29
- 1 month ago 29
- 2 months ago 30
- 3 months ago 31
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 3.89 | 3.84 – 4.01 | 2.71 | +43.6% | 18.41B | +10.8% | 18 |
| Next quarter | 3.45 | 3.30 – 3.90 | 2.65 | +30.1% | 16.43B | +9.6% | 8 |
| Current year | 14.00 | 13.93 – 14.13 | 10.00 | +40.0% | 67.82B | +10.9% | 22 |
| Next year | 16.18 | 15.17 – 17.23 | 14.00 | +15.6% | 73.79B | +8.8% | 28 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Nov 2, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 2, 2026 | Guggenheim | Maintained | Buy | Buy |
| Nov 2, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 2, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 2, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 2, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Oct 23, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 21, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 13, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Oct 9, 2026 | UBS | Maintained | Neutral | Neutral |
| Oct 9, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Oct 8, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 8, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 6, 2026 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Sep 10, 2026 | HSBC | Maintained | Buy | Buy |
| Aug 20, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 17, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 13, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Aug 11, 2026 | BNP Paribas | Maintained | Neutral | Neutral |
| Aug 10, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Berenberg | Maintained | Buy | Buy |
| Aug 5, 2026 | Erste Group | Upgrade | Hold | Buy |
| Aug 4, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 3, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 3, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 31, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 31, 2026 | William Blair | Maintained | Buy | Buy |